Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies
Published: 30 Mar 2026
Author: Precedence Research
Excalipoint Therapeutics, it is a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases. It announced a $68.7 million seed financing round to support the advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs. The seed round represents one of the largest early-stage financings for a Chinese biotechnology company.
Co-Founder, Chief Financial Officer, and Chief Business Officer Jielun Zhu said a successful launch and backing from top-tier investors highlight Excalipoint’s strong growth potential.
Market Outlook and Growth Potential
According to Towards Healthcare, the clinical stage biotechnology market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 54.66 billion in 2026 to approximately USD 205.32 billion by 2035, representing a compound annual growth rate (CAGR) of 15.84% from 2026 to 2035. This market has programs which are designed to improve the efficacy, safety, and durability of T-cell immunotherapies for solid tumours and other difficult-to-treat cancers.
Innovation in T-Cell Engager Platforms
Excalipoint’s next-generation platforms are designed to overcome key biological barriers that have historically limited T-cell engager therapies, including converting “cold” tumours into “hot” tumours, addressing the tumour microenvironment, and enabling targeting of difficult-to-drug tumour antigens. Supported by these proprietary platforms, the company is building a diversified pipeline to reduce single-asset risk and drive value through strategic partnerships and out-licensing.
PhD, Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics Lei Fang said Excalipoint is developing a proprietary pipeline and three powerful technology platforms to position our company as a true innovation powerhouse and developer of T-cell engagers.
A combination of science and capital, with China’s clinical development efficiency and access to large patient populations generating a high volume of clinical data while advancing a pipeline of differentiated therapies.
MPCi empowers Excalipoint in the Next Generation
Founding Managing Partner, MPCi, David Su, said it is deeply engaged in healthcare, focusing on science-driven innovative enterprises with core technological barriers. Excalipoint is our highly recognised next-generation TCE innovation powerhouse. MPCi will empower Excalipoint to unlock the enormous value of T-cell immunotherapy and become a global innovation benchmark.
Executive Director at Centurium Capital, Vicky Li, gave a statement that Centurium Capital’s investment thesis focuses on identifying companies capable of driving transformative innovation, and we believe Excalipoint is among the most promising next-generation TCE companies globally.
A recent report by Towards Healthcare on the clinical stage biotechnology market highlights robust growth driven by increasing investments in drug development and rising clinical trial activity worldwide. Advancements in genomics, personalized medicine, and biologics, coupled with supportive regulatory pathways and strategic collaborations, are accelerating innovation and expanding the global clinical-stage biotechnology pipeline significantly.